Physician profile
Amy Cobb
NPI 1144209081
$2,414.06
in general payments reported to CMS, 2019-2025
32 companies · $591 in 2025
The $591 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $296 · 2023: $668 · 2024: $720 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,979.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $326.31 | 2021-2025 | |
| Lilly USA, LLC | $246.55 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $231.83 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Vanda Pharmaceuticals INC. | $223.02 | 2024-2025 | Hetlioz, Fanapt |
| Glaxosmithkline, LLC. | $184.73 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $133.36 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $132.14 | 2022-2025 | |
| Amgen INC. | $115.10 | 2023-2025 | Repatha, Otezla, Evenity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.16 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $88.76 | 2023-2024 | Austedo Xr, Uzedy |
| Ironshore Pharmaceuticals INC. | $81.29 | 2022-2024 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $55.59 | 2025 | |
| Lundbeck LLC | $51.95 | 2022-2024 | Rexulti |
| Axsome Therapeutics, INC. | $50.64 | 2023-2024 | Auvelity |
| Exact Sciences Corporation | $49.66 | 2023-2024 | Cologuard Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $43.38 | 2023 | Breztri, Farxiga |
| Abbott Laboratories | $34.89 | 2022-2023 | Freestyle Libre 2 |
| Neurocrine Biosciences, INC. | $29.27 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.15 | 2021-2025 | Trintellix |
| Insulet Corporation | $24.40 | 2023 | Omnipod |
| Tris Pharma INC | $19.30 | 2025 | Dyanavel Xr |
| Inogen, INC. | $18.82 | 2022 | |
| Endo USA, INC. | $18.74 | 2024 | Xiaflex |
| Dynavax Technologies Corporation | $17.64 | 2025 | Heplisav-B |
| Inspire Medical Systems, INC. | $16.90 | 2025 | Inspire |
| Alnylam Pharmaceuticals INC. | $16.27 | 2025 | Givlaari |
| Collegium Pharmaceutical, INC. | $15.63 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $15.53 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Boston Scientific Corporation | $14.11 | 2022 | |
| Pfizer INC. | $13.50 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.04 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Cobb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.